Neurological Sciences

, Volume 32, Issue 3, pp 387–392 | Cite as

Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life

  • Alberto Raggi
  • Matilde Leonardi
  • Gennaro Bussone
  • Domenico D’Amico
Original Article


The aim of this paper is to explore the relationships between health-related quality of life (HRQoL), assessed with the Short Form-36 (SF-36), and disability in adult migraineurs using both disease-specific and generic tools, the WHO Disability Assessment Schedule II (WHO-DAS II) and with the Migraine Disability Assessment questionnaire (MIDAS). Significant differences were observed between patients with minimal/mild and moderate/severe MIDAS disability grades for Role Physical, Bodily Pain, General Health, Vitality, Social Functioning and Physical Composite Score of the SF-36; in the WHO-DAS II for household activities, participation in society and for summary score. WHO-DAS II and MIDAS provide complementary information on the intensity and the frequency of problems in performing daily activities, and could be used jointly. Our findings indicate that these issues are relevant for patients’ health status and should be taken into account in future research on migraine as important secondary outcomes of treatment interventions.


WHO-DAS II MIDAS SF-36 Disability Health-related quality of life Migraine 


  1. 1.
    Freitag F (2007) The cycle of migraine: patients’ quality of life during and between migraine attacks. Clin Ther 29:939–949PubMedCrossRefGoogle Scholar
  2. 2.
    Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF (2003) Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 23:441–450PubMedCrossRefGoogle Scholar
  3. 3.
    Stovner Lj, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193–210PubMedCrossRefGoogle Scholar
  4. 4.
    Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D’Amico D (2004) Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci 25:S105–S107PubMedCrossRefGoogle Scholar
  5. 5.
    Murray CJL, Lopez AD, Mathers CD, Stein C (2000) WHO Burden Series paper 36: The Global Burden of Disease 2000 project: aims, methods and data sources. WHO, GenevaGoogle Scholar
  6. 6.
    World Health Organization (2001) The World Health Report 2001: Mental health, new understanding new hope. WHO, GenevaGoogle Scholar
  7. 7.
    Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J (2005) Cost of migraine and other headaches in Europe. Eur J Neurol 12:S1–S27CrossRefGoogle Scholar
  8. 8.
    Berg J, Stovner LJ (2005) Cost of migraine and other headaches in Europe. Eur J Neurol 12:S59–S62CrossRefGoogle Scholar
  9. 9.
    Massetto N, Gambini C, Bernardoni P, Ferrante E, Lovati C, Moschiano F, Tonini MC, Bussone G, D’Amico D (2009) Underdiagnosis of primary headaches: results of a survey on patients attending headache centres. Neurol Sci 30:S129–S131PubMedCrossRefGoogle Scholar
  10. 10.
    Lipton RB, Stewart WF (1993) Migraine in the United States: a review of epidemiology and health care use. Neurology 43:6–10Google Scholar
  11. 11.
    Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L, Finlayson G, Wright P, Biondi D, on behalf of the AEGIS Investigator Study Group (2008) Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS trial. Headache 48:341–354PubMedCrossRefGoogle Scholar
  12. 12.
    D’Amico D, Solari A, Usai S, Santoro P, Bernardoni P, Frediani F, De Marco R, Massetto N, Bussone G, Progetto Cefalee Lombardia Group (2006) Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia 26:691–696PubMedCrossRefGoogle Scholar
  13. 13.
    Dahlöf C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L (2007) The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes 5:56PubMedCrossRefGoogle Scholar
  14. 14.
    Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1). Headache 40:204–215PubMedCrossRefGoogle Scholar
  15. 15.
    Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD (1995) Validation of a new quality of life questionnaire for acute migraine headache. Headache 35:330–337PubMedCrossRefGoogle Scholar
  16. 16.
    Ware JE (2000) SF-36 health survey update. Spine 25:3130–3139PubMedCrossRefGoogle Scholar
  17. 17.
    Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J (1999) Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 19:1–96CrossRefGoogle Scholar
  18. 18.
    World Health Organization (2001) The international classification of functioning, disability and health-ICF. WHO, GenevaGoogle Scholar
  19. 19.
    Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Del Río MS, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054–1062PubMedCrossRefGoogle Scholar
  20. 20.
    Fuh JL, Wang SJ (2006) Comparison of Short Form-36 and migraine disability assessment questionnaire in patients with migraine. Clin J Pain 22:564–568PubMedCrossRefGoogle Scholar
  21. 21.
    D’Amico D, Usai S, Solari A, Grazzi L, Leone M, Rigamonti A, Bussone G (2003) Relationship between disability and quality of life in migraine. In: Olesen J, Steiner TS, Lipton RB (eds) Reducing the burden of headache. Oxford University Press, New York, pp 75–78Google Scholar
  22. 22.
    Raggi A, Leonardi M, Ajovalasit D, D’Amico D, Bussone G (2010) Disability and functional profiles of patients with migraine measured with ICF classification. Int J Rehabil Res 32:225–231Google Scholar
  23. 23.
    Ustun TB (1999) WHO-DAS II field trials report 1998. WHO, GenevaGoogle Scholar
  24. 24.
    Cankurtaran ES, Ulug B, Saygi S, Tiryaki A, Akalan N (2005) Psychiatric morbidity, quality of life, and disability in mesial temporal lobe epilepsy patients before and after anterior temporal lobectomy. Epilepsy Behav 7:116–122PubMedCrossRefGoogle Scholar
  25. 25.
    Martinuzzi A, Liava A, Trevisi E, Frare M, Tonon C, Malucelli E, Manners D, Kemp GJ, Testa C, Barbiroli B, Lodi R (2008) Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle’s disease. Muscle Nerve 37:350–357PubMedCrossRefGoogle Scholar
  26. 26.
    Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, Cornelio F, Mantegazza R (2010) The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study. J Neurol 257:98–102PubMedCrossRefGoogle Scholar
  27. 27.
    Raggi A, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio F, Mantegazza R (2010) Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis. Neurol Sci 31:41–45PubMedCrossRefGoogle Scholar
  28. 28.
    Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders. Cephalalgia 24:S1–S160Google Scholar
  29. 29.
    D’Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, Leone M, Puca FM, Bussone G (2001) The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 21:947–952PubMedCrossRefGoogle Scholar
  30. 30.
    Federici S, Meloni F, Mancini A, Lauriola M, Olivetti Belardinelli M (2009) World Health Organisation Disability Assessment Schedule II: contribution to the Italian validation. Disabil Rehabil 31:553–564PubMedCrossRefGoogle Scholar
  31. 31.
    Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036PubMedCrossRefGoogle Scholar
  32. 32.
    Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53:988–994PubMedGoogle Scholar
  33. 33.
    Silberstein SD, Loder E, Forde G, Papadopulos G, Fairclough D, Greenberg S (2006) The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin 22:1021–1029PubMedCrossRefGoogle Scholar
  34. 34.
    Lipton RB, Bigal ME, Stewart WF (2005) Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 65:S50–S58PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Alberto Raggi
    • 1
  • Matilde Leonardi
    • 1
  • Gennaro Bussone
    • 2
  • Domenico D’Amico
    • 2
  1. 1.Neurology, Public Health and Disability Unit, Scientific DirectorateNeurological Institute C. Besta, IRCCS FoundationMilanItaly
  2. 2.Headache CentreNeurological Institute C. Besta, IRCCS FoundationMilanItaly

Personalised recommendations